We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Marina Biotech Initiates Dosing in the Phase 1b/2a START-FAP Clinical Trial of CEQ508

News   Apr 08, 2011

 
Marina Biotech Initiates Dosing in the Phase 1b/2a START-FAP Clinical Trial of CEQ508
 
 
 

RELATED ARTICLES

Protein Interactions Shed Light on Ebola Virus Replication

News

Researchers have discovered the interaction between an Ebola virus protein and a protein in human cells that may be an important key to unlocking the pathway of replication of the killer disease in human hosts.

READ MORE

Blindness Prevented in Animal Models of Retinal Degeneration

News

Using a novel patient-specific stem cell-based therapy, blindness was prevented in animal models of geographic atrophy, the advanced 'dry' form of age-related macular degeneration (AMD), which is a leading cause of vision loss among people age 65 and older.

READ MORE

Poo Transplant Shows Promise in Prelim Study for Ulcerative Colitis

News

Anaerobically prepared fecal microbiota transplantation improved remission rates in people with moderately active ulcerative colitis at 8 weeks. Further research is needed to assess longer-term efficacy and safety.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE